The biological understanding derived from deep sequencing of clinically annotated tumours may improve outcomes for people with cancer. Cohorts of neuroendocrine tumours from several different primary sites have now been sequenced. This lecture will discuss implications for the clinic. To date there are no easy links between individual gene mutations and individual therapies. Nonetheless, pockets of clinically relevant information are emerging from NET genomics that will begin to inform clinical practice as our expectations of precision medicine mature.